louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05899803: Use of Walkers in Infancy and Musculoskeletal System
Official title: The Effect of the Use of a Walker in Infancy on the Musculoskeletal System and the Level of Physical Activity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Use of a Walker in Infancy
Physical Activity Level
Musculoskeletal Problems
Keywords: Baby equipment
physical activity
muscle strength
posture
walker
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2023-06-12
Enrollment: 39
Sex: ALL
Minimum age (years): 8
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of this study was to compare lower extremity muscle strength, posture disorders and physical activity levels of children with and without walker use during infancy. Thirty-nine children aged between 8 and 15 years were included. Demographic data, New York Posture Analysis Questionnaire and Physical Activity Assessment Questionnaire Scale (PAQ-C) were collected. Muscle strength was measured with a digital muscle strength meter.

Detailed description: This study aimed to compare lower extremity muscle strength, postural disorders, and physical activity levels of children who used and did not use a walker during infancy.

The study included 39 children aged between 8 and 15 years. The demographic information of the children, their motor development stages and walker use situations, the age at which they started using it, and the duration of use were questioned. The New York Posture Analysis Questionnaire and Physical Activity Assessment Questionnaire Scale (PAQ-C) were administered to the children. Muscle strength was measured with a digital muscle strength meter.

Eligibility criteria: Inclusion Criteria:

* No idiopathic serious orthopedic problems
* No chronic disease
* Children and their parents who volunteered to participate in the study

Exclusion Criteria:

* Presence of neurologic disease.
* Presence of neuromuscular disease.
* Presence of mental retardation.

Primary outcomes:
measure: Muscle strength
timeFrame: 6 months
measure: Physical activity level
timeFrame: 6 months
Secondary outcomes:
measure: Posture analysis
timeFrame: 6 months
Other outcomes:
Locations:
city: Izmir
country: Turkey
facility: Ege university faculty of health sciences
state: Karsıyaka
Study officials:
References:
Clinical trial NCT01750203: Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay
Official title: Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Wounds With Different Etiologies
Keywords: Diabetic foot ulcers, venous leg ulcers, pressure sores, acute wounds
Lead sponsor: Systagenix Wound Management
Sponsor class: INDUSTRY
First posted: 2012-12-17
Enrollment: 135
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult subjects (greater than 18 years old), presenting at participating clinical sites with wounds of different etiologies, who are willing to provide informed consent and who meet the inclusion / exclusion criteria, will be prospectively enrolled

Brief summary: The objective of this study is to collect wound exudate (fluid) swab samples from Subjects who have wounds that show clinical signs of infection, as well as from Subjects who have wounds that do not show clinical signs of infection. Swab samples will be collected from acute and chronic wounds of different etiologies and these will be analysed for bacteria types and markers of infection.


Eligibility criteria: Inclusion Criteria:

* Subject has presented to participating study site with a wound(s) suspected to be infected, as determined by the Investigator and/ or study staff - defined as one that through clinical judgment has questionable infection status, and /or shows three or more of the NERDS or STONES signs of infection);
* Subject has presented to participating study site with a wound(s) suspected not to be infected, as determined by the Investigator and/ or study staff - defined as one that does not show three or more of the NERDS or STONES signs of infection.
* Subject is 18 years of age or older.
* Subject agrees to complete all aspects of the study and provides Informed Consent

Exclusion Criteria:

* Subject is less than 18 years of age.
* Target wound contains a malignancy
* Subject has hypersensitivity of the wound or painful wound surface which prevents touching/swabbing of the wound surface.
* Subject is confirmed to be positive for HIV or hepatitis.
* Subject is unable or unwilling to provide informed consent.
* Subjects deemed inappropriate for the study by the site's Principal Investigator.

Primary outcomes:
measure: The biochemical differences between clinically infected and non infected wounds.
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Tulsa
country: United States
facility: St. John Wound Center
state: Oklahoma
Study officials:
affiliation: SerenaGroup, Inc.
name: Tom Serena, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00312403: Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?
Official title: Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: Glaucoma
Gene Polymorphism
Metalloproteinase
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2006-04-10
Enrollment: 400
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Matrix metalloproteinases (MMPs) fulfill diverse important molecular functions and play pivotal roles in development, tissue morphogenesis, repair, aging, and inflammatory processes. MMPs are also important disease modulating factors, such as cancer, cardiovascular disease, rheumatoid arthritis or macular degeneration. Functional genetic variants have been described to fine-tune MMP activities at the gene transcriptional level and have been associated with increased genetic risk of e.g. arteriosclerosis or cancer. MMPs are also assumed to play a major role in the remodeling of the extracellular matrix (ECM) in the optic nerve head during glaucomatous optic neuropathy. MMP-1, MMP-3 and MMP-9 have been shown to be up-regulated in a variety of animal models of glaucoma. Here, we study three promoter SNPs within the genes encoding three members of the MMP family. By assessing the prevalence of genetic variants associated with either increased/decreased enzyme activity, we will (i) estimate their contribution to the genetic risk of developing primary open angle glaucoma (POAG) and (ii) investigate the potential role of MMPs in the functional pathology of POAG.


Eligibility criteria: Inclusion Criteria:

* Men and women older than 39 years
* Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
* Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)

Exclusion Criteria:

* Exfoliation glaucoma, pigmentary glaucoma
* History of acute angle closure

Primary outcomes:
measure: Genotyping results and putatively associated odds with occurence of primary open angle glaucoma.
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Clinical Pharmacology
Study officials:
affiliation: Department of Clinical Pharmacology, Medical University of Vienna
name: Gabriele Fuchsjaeger-Mayrl, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01820403: Portion Size Effects on Body Weight:Free Living Setting
Official title: Portion Size Effects on Body Weight: Free Living Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Portion Sizes
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2013-03-28
Enrollment: 233
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study purpose was to evaluate the effects of portion sizes on body weight and energy intake in a free-living setting. 223 healthy adults were recruited from an urban worksite and randomized to one of four groups for a six-month period. The groups were: 1) 400 kcal box lunch; 2) 800 kcal box lunch; 3) 1600 kcal box lunch; or 4) no box lunch. Participants were required to pick up a box lunch every week day for six months. Control participants did not receive a box lunch and were instructed to eat their usual lunch. Participants were weighed and dietary intake measured at baseline, one, three and six months. It was hypothesized that at six months, participants in the 1600 kcal box lunch would gain more weight and have higher energy intake than those in the other groups.


Eligibility criteria: Inclusion Criteria:

* : 1) age 18-60 yrs; 2) nonsmoker; 3) fluent in English; 4) not taking medications that affect appetite or body weight; 5) work at the medical complex full time, including during the lunch hours; 6) not allergic to the foods in the study lunches; 7) willing to eat the foods in the study lunches \[examples were provided of the types of foods\]; 8) not currently on a diet to lose weight; 9) no history of a diagnosed eating disorder; 10) not moving from the area during the next six months; 11) not currently taking part in another research study; 12) not currently pregnant, nursing or pregnant in the last 12 months.

Exclusion Criteria: if the person does not meet the criteria above

-

Primary outcomes:
measure: body weight change
timeFrame: six months
Secondary outcomes:
measure: dietary energy intake
timeFrame: six months
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
References:
Clinical trial NCT00335803: A Research Study To Compare Two Kinds Of Daily Headache
Official title: A Comparison Of Subjects With New Daily Persistent Headache (NDPH) And Subjects With Transformed Migraine (TM)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Migraine
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2006-06-12
Sex: ALL
Minimum age (years): 14
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: Chronic daily headache has been classified into several categories. One category is of sudden onset and is called New Daily Persistent Headache (NDPH). Another category of daily headache evolves gradually and is called Transformed Migraine (TM). This research study is being conducted to compare people with these two kinds of daily headache in order to improve our understanding of these conditions.


Eligibility criteria: Inclusion Criteria:

* Male and female patients aged 14-65, inclusive
* Diagnosis of NDPH or TM according to the Silberstein-Lipton criteria.
* Ability to read and understand an informed consent form and study procedures

Exclusion Criteria:

* Pregnancy
* Subjects with any disease or condition that would result in unreliable data or confound the data obtained for this study, as determined by the principal investigator.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Jefferson Headache Center
state: Pennsylvania
Study officials:
affiliation: Jefferson Headache Center
name: william b young, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01622803: Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction
Official title: Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Bile Duct Neoplasm
Obstructive Jaundice
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2012-06-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Internal biliary drainage using stent is used for malignant hilar obstruction such as cholangiocarcinoma, hepatocellular carcinoma and other malignancy including metastasis.

Bilateral drainage is more physiologic and have more long patency than unilateral drainage.

There are two methods of bilateral drainage: Y-stent and side by side.

However there are no clinical data about comparing the effectiveness of these two methods.

Therefore the investigators want to compare the clinical outcomes of two methods:

Y-stent and side by side.


Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years
* patient who have obstructive jaundice (bilirubin \> 2.0mg/dl) due to hilar malignancy

Exclusion Criteria:

* patients with endoscopic retrograde cholangiogram is not possible
* bleeding tendency (PT INR \> 1.5, platelet \< 50,000)
* poor general condition (ECOG 3-4) or cardiopulmonary deterioration
* pregnancy

Primary outcomes:
measure: The time taken to insert bilateral stent
timeFrame: After the ERCP procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Division of Gastroenterology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
name: Kwang hyuck Lee, MD, phD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00002103: A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia
Official title: A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections
Keywords: Trimetrexate
Pneumonia, Pneumocystis carinii
Leucovorin
Drug Therapy, Combination
Acquired Immunodeficiency Syndrome
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in European patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).

Detailed description: Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate. Patients are followed for 1 month.

Eligibility criteria: Inclusion Criteria

Patients must have:

* Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry.
* Serious intolerance and/or resistance to standard therapies (such as trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of therapy for the current episode of PCP, OR a documented history of such intolerance during a prior episode.
* Consent of parent or guardian if less than 18 years of age.

Exclusion Criteria

Patients with the following prior conditions are excluded:

History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions due to trimetrexate glucuronate.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: West Conshohocken
country: United States
facility: United States Bioscience Inc
state: Pennsylvania
Study officials:
References:
citation: Feinberg J, McDermott C, Nutter J. Trimetrexate (TMTX) salvage therapy for PCP in AIDS patients with limited therapeutic options. Int Conf AIDS. 1992 Jul 19-24;8(2):B136 (abstract no PoB 3297)
Clinical trial NCT05940103: Augmented Reality (AR) Hong Kong
Official title: International Training of Non-Technical Medical Crisis Skills Using Remote, Augmented Reality Simulation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Educational Problems
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2023-07-11
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is an international, collaborative study evaluating the non-technical skills (NTS) of anesthesiology residents. The goal is to explore the capability of performing a remote, international AR simulation for the purpose of assessing PALS during a medical crisis. Simulation experts in the United States will facilitate the AR simulations with anesthesiology residents in Hong Kong. The medical simulation itself is grounded in traditional best practices in accordance with the American Heart Association.


Eligibility criteria: Inclusion Criteria:

* age above 18

Exclusion Criteria:

* a history of severe motion sickness
* currently have nausea, a history of seizures
* wear corrective glasses (they are not compatible with the AR hardware).

Primary outcomes:
measure: Individual performance of non-technical skills assessed by Anaesthetist Non-Technical Skills (ANTS)
timeFrame: immediately after simulation
Secondary outcomes:
measure: Individual performance of non-technical skills assessed by Behaviorally Anchored Rating Scale (BARS)
timeFrame: immediately after simulation
measure: System Usability Scale (SUS) Score
timeFrame: immediately after simulation
measure: The International Organization for Standardization (ISO) Ergonomic scale
timeFrame: immediately after simulation
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Lucile Parkard Children's Hospital
state: California
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital
Study officials:
affiliation: Stanford University
name: Thomas J Caruso, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01972503: Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
Official title: A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Keywords: Colorectal Neoplasms
Liver
Neoplasm Metastasis
Tegafur
oxaliplatin
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2013-10-30
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, the investigators assessed whether intraoperative Intraportal infusion of 5-FU and oxaliplatin is able to prevent liver metastasis in patients receiving curative colorectal cancer resection.

Detailed description: In this study, the investigators assessed whether intraoperative Intraportal infusion of 5-FU and oxaliplatin is able to prevent liver metastasis and improve survival in patients with Stage II or Stage III colorectal cancer without apparent liver metastasis based on a thorough preoperative evaluation.

Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms.Arm A: 5-FU 1g and oxaliplatin 100mg + curative resection (study group, n=132). Arm B: curative resection alone (control group, n=132).Follow-up: X-ray, US, CT, blood test, colonoscopy,every 3months.

The study endpoints were disease-free survival, overall survival, and liver metastasis-free survival as evaluated by intent-to-treat analysis.

Eligibility criteria: Inclusion criteria

1. Age ≥ 18 and ≤ 75 years and with histologically proven adenocarcinoma of the colon or rectum
2. WHO performance status of 0 or 1
3. Stage II (T3-4, N0, M0) or Stage III (T0-4, N1-2, M0) disease (according to the 1997 revision of the International Union Against Cancer TNM staging system) as determined by a preoperative evaluation that included colonoscopy and an abdominal computed tomography (CT) scan
4. Written informed consent for participation in the trial.

Exclusion criteria

1. has prior other malignant cancer
2. has severe major organ dysfunction
3. has prior cancer therapy before surgery

Primary outcomes:
measure: 3 years disease-free survival
timeFrame: 3 years after operation
Secondary outcomes:
measure: 3 years overall survival and metastasis-free survival
timeFrame: 3 years after operation
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital, Fudan University
state: Shanghai
Study officials:
References:
citation: Chang W, Wei Y, Ren L, Zhong Y, Yu Y, Chen J, Zhu D, Ye L, Qin C, Zhao N, Niu W, Qin X, Xu J. Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer. Ann Surg. 2016 Mar;263(3):434-9. doi: 10.1097/SLA.0000000000001374.
Clinical trial NCT05847803: Patient Monitoring in the Intensive Care Unit
Official title: Nurses' Perceptions of Patient Monitoring in the Intensive Care Unit: a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Medical Informatics
Intensive Care
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-05-08
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: registered nurses in the ICUs

Brief summary: a cross-sectional survey of nurses' perception of patient monitoring in the ICUs


Eligibility criteria: Inclusion Criteria:

* registered nurses in the ICUs

Exclusion Criteria:

-

Primary outcomes:
measure: clinical requirements of patient monitoring in ICUs
timeFrame: 12 months of working
measure: Work-related flow in ICUs
timeFrame: 12 months of working
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: SAHZhejiangU
Study officials:
affiliation: SAHZU
name: Wen Gao, PhD
role: STUDY_CHAIR
References: